Wall Street analysts expect Audentes Therapeutics Inc (NASDAQ:BOLD) to report earnings per share (EPS) of ($0.90) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Audentes Therapeutics’ earnings, with estimates ranging from ($1.03) to ($0.87). Audentes Therapeutics posted earnings per share of ($0.74) in the same quarter last year, which would indicate a negative year over year growth rate of 21.6%. The company is scheduled to report its next earnings results on Wednesday, May 8th.
On average, analysts expect that Audentes Therapeutics will report full-year earnings of ($3.80) per share for the current year, with EPS estimates ranging from ($4.46) to ($3.47). For the next financial year, analysts forecast that the firm will report earnings of ($3.66) per share, with EPS estimates ranging from ($4.21) to ($2.51). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Audentes Therapeutics.
Audentes Therapeutics (NASDAQ:BOLD) last announced its earnings results on Wednesday, February 27th. The biotechnology company reported ($0.84) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.08. During the same quarter in the previous year, the business earned ($0.82) EPS.
A number of brokerages have weighed in on BOLD. HC Wainwright reiterated a “buy” rating and set a $44.00 target price (up from $33.00) on shares of Audentes Therapeutics in a research note on Monday, March 18th. William Blair reissued a “hold” rating on shares of Audentes Therapeutics in a research report on Wednesday, February 27th. ValuEngine raised shares of Audentes Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Monday, April 1st. Zacks Investment Research raised shares of Audentes Therapeutics from a “hold” rating to a “buy” rating and set a $28.00 price objective for the company in a research report on Tuesday, January 8th. Finally, Piper Jaffray Companies boosted their price objective on shares of Audentes Therapeutics from $45.00 to $55.00 and gave the company a “positive” rating in a research report on Monday, April 8th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $37.99.
In other Audentes Therapeutics news, CEO Matthew R. Patterson sold 21,000 shares of the stock in a transaction dated Monday, February 25th. The shares were sold at an average price of $30.00, for a total transaction of $630,000.00. Following the completion of the transaction, the chief executive officer now owns 135,700 shares of the company’s stock, valued at approximately $4,071,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Louis G. Lange sold 20,000 shares of the stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $36.00, for a total transaction of $720,000.00. Following the transaction, the director now directly owns 306,099 shares of the company’s stock, valued at approximately $11,019,564. The disclosure for this sale can be found here. Insiders sold a total of 51,000 shares of company stock valued at $1,650,600 in the last ninety days. 6.60% of the stock is currently owned by insiders.
Several institutional investors and hedge funds have recently added to or reduced their stakes in BOLD. NumerixS Investment Technologies Inc boosted its holdings in shares of Audentes Therapeutics by 1,200.0% during the 4th quarter. NumerixS Investment Technologies Inc now owns 1,300 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 1,200 shares during the last quarter. Amundi Pioneer Asset Management Inc. bought a new position in shares of Audentes Therapeutics during the 4th quarter valued at about $92,000. Great West Life Assurance Co. Can boosted its holdings in shares of Audentes Therapeutics by 96.0% during the 4th quarter. Great West Life Assurance Co. Can now owns 4,726 shares of the biotechnology company’s stock valued at $97,000 after purchasing an additional 2,315 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its holdings in shares of Audentes Therapeutics by 46.1% during the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 6,280 shares of the biotechnology company’s stock valued at $138,000 after purchasing an additional 1,983 shares during the last quarter. Finally, Legal & General Group Plc boosted its holdings in shares of Audentes Therapeutics by 34.5% during the 4th quarter. Legal & General Group Plc now owns 6,632 shares of the biotechnology company’s stock valued at $141,000 after purchasing an additional 1,700 shares during the last quarter.
BOLD traded down $0.54 during mid-day trading on Wednesday, reaching $40.46. 1,394 shares of the company traded hands, compared to its average volume of 477,942. The firm has a market cap of $1.75 billion, a PE ratio of -11.90 and a beta of 1.96. Audentes Therapeutics has a 52-week low of $17.95 and a 52-week high of $46.18.
About Audentes Therapeutics
Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.
Featured Article: What is net income?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.